Tarlatamab
Tarlatamab (Imdylltra, Amgen Europe B.V.) has 1 EU-approved indication in 1 tumour type.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Small cell lung cancer1 | |||
None | Monotherapy | 2L advanced | Disease progression on or after first-line treatment with platinum-based chemotherapy; Who require systemic therapy |
Full text of section 4.1 (therapeutic indications)
IMDYLLTRA is indicated as monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.
Label history
There is no record of changes to the Imdylltra label that oncolabels can read yet. EMA publishes it some months after the first approval.